Table 3.
Multivariable Cox Proportional Hazards Model OS According to Breast Cancer Subtypea
| Characteristic | Breast Cancer Subtype, HR (95% CI) | ||
|---|---|---|---|
| Hormone Receptor Positive | ERBB2+ | TNBC | |
| TTC, d | |||
| <31 | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| 31-60 | 0.90 (0.75-1.08) | 0.97 (0.77-1.24) | 1.09 (0.90-1.31) |
| 61-90 | 0.95 (0.77-1.18) | 1.03 (0.76-1.38) | 1.08 (0.85-1.36) |
| ≥91 | 1.25 (0.98-1.59) | 1.28 (0.93-1.75) | 1.53 (1.17-2.00) |
| Age at diagnosis, y | |||
| 0-40 | 0.90 (0.70-1.15) | 0.64 (0.47-0.88) | 0.90 (0.70-1.15) |
| 41-59 | 0.62 (0.53-0.73) | 0.58 (0.47-0.72) | 0.73 (0.61-0.88) |
| 60-79 | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| ≥80 | 2.94 (1.89-4.59) | 2.11 (1.33-3.36) | 2.05 (1.35-3.11) |
| Sex | |||
| Female | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Male | 1.73 (1.02-2.94) | 1.12 (0.42-3.01) | 0.46 (0.06-3.34) |
| Race/ethnicity | |||
| Non-Hispanic white | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Non-Hispanic black | 1.21 (0.94-1.57) | 1.36 (0.98-1.89) | 1.26 (1.01-1.57) |
| Hispanic | 0.76 (0.63-0.93) | 0.86 (0.67-1.11) | 0.92 (0.75-1.13) |
| Asian/Pacific Islander | 0.72 (0.56-0.92) | 0.83 (0.61-1.12) | 0.85 (0.64-1.12) |
| Non-Hispanic American Indian/other/unknown | 1.58 (0.89-2.80) | 0.36 (0.09-1.46) | 0.89 (0.37-2.16) |
| AJCC stage at diagnosis | |||
| I | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| II | 1.56 (1.24-1.95) | 2.59 (1.87-3.59) | 2.08 (1.68-2.58) |
| III | 3.76 (3.00-4.72) | 7.46 (5.41-10.3) | 5.72 (4.56-7.18) |
| Neighborhood SES | |||
| 1 (lowest) | 1.60 (1.25-2.06) | 1.66 (1.18-2.32) | 1.22 (0.94-1.58) |
| 2 | 1.57 (1.26-1.96) | 1.53 (1.12-2.09) | 1.11 (0.87-1.41) |
| 3 | 1.31 (1.06-1.63) | 1.43 (1.06-1.93) | 1.22 (0.97-1.53) |
| 4 | 1.35 (1.10-1.66) | 1.20 (0.88-1.63) | 1.04 (0.83-1.31) |
| 5 (highest) | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Marital status | |||
| Married | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Not currently married | 1.08 (0.93-1.24) | 1.03 (0.85-1.26) | 1.10 (0.94-1.29) |
| Unknown | 0.97 (0.57-1.65) | 1.93 (1.05-3.56) | 0.98 (0.58-1.68) |
| Primary payer/insurance | |||
| Medicare | 1.82 (1.45-2.29) | 1.19 (0.84-1.68) | 1.11 (0.84-1.46) |
| Military | 0.51 (0.16-1.59) | 1.12 (0.41-3.03) | 1.09 (0.41-2.94) |
| Not insured/self-pay | 1.60 (0.79-3.23) | 0.97 (0.36-2.62) | 0.90 (0.37-2.19) |
| Private | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Medicaid | 1.76 (1.47-2.10) | 1.44 (1.15-1.81) | 1.20 (0.99-1.47) |
| Unknown | 0.90 (0.56-1.44) | 0.79 (0.46-1.33) | 0.85 (0.56-1.30) |
| NCI-designated cancer center | |||
| No | 1 [Reference] | 1 [Reference] | 1 [Reference] |
| Yes | 0.61 (0.44-0.86) | 0.69 (0.44-1.08) | 0.74 (0.53-1.04) |
Abbreviations: AJCC, American Joint Committee on Cancer; ERBB2+, human epidermal growth factor receptor 2-positive; HR, hazard ratio; NCI, National Cancer Institute; OS, overall survival; SES, socioeconomic status; TTC, time to chemotherapy.
a
Models adjusted for individual year of diagnosis.